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ABSTRACT
Increased mRNA translation drives carcinogenesis and is an attractive target 
for the development of new anti-cancer drugs. In this work, we investigated effects 
of phenethylisothiocyanate (PEITC), a phytochemical with chemopreventive and  
anti-cancer activity, on mRNA translation. PEITC rapidly inhibited global mRNA 
translation in human breast cancer-derived MCF7 cells and mouse embryonic 
fibroblasts (MEFs). In addition to the known inhibitory effects of PEITC on mTORC1 
activity, we demonstrate that PEITC increased eIF2α phosphorylation. PEITC also 
increased formation of stress granules which are typically associated with eIF2α 
phosphorylation and accumulation of translationally stalled mRNAs. Analysis of 
genetically modified MEFs demonstrated that optimal inhibition of global mRNA 
translation by PEITC was dependent on eIF2α phosphorylation, but not mTORC1 
inhibition. We extended this study into primary leukemic B cells derived from patients 
with chronic lymphocytic leukaemia (CLL). CLL cells were stimulated in vitro with  
anti-IgM to mimic binding of antigen, a major driver of this leukemia. In CLL cells, 
PEITC increased eIF2α phosphorylation, inhibited anti-IgM-induced mTORC1 activation 
and decreased both basal and anti-IgM-induced global mRNA translation. PEITC also 
inhibited transcription and translation of MYC mRNA and accumulation of the MYC 
oncoprotein, in anti-IgM-stimulated cells. Moreover, treatment of CLL cells with PEITC 
and the BTK kinase inhibitor ibrutinib decreased anti-IgM-induced translation and 
induced cell death to a greater extent than either agent alone. Therefore, PEITC 
can inhibit both global and mRNA specific translation (including MYC) via effects on 
multiple regulatory pathways. Inhibition of mRNA translation may contribute to the 
chemopreventive and anti-cancer effects of PEITC.
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INTRODUCTION
Phenethyl isothiocyanate (PEITC) is a naturally 
occurring phytochemical that has received extensive 
interest for its anti-cancer and chemopreventive activities.
[1] PEITC induces cell cycle arrest and apoptosis, 
and inhibits metastasis, proliferation and angiogenesis 
in various malignant cell types and, therefore, has 
inhibitory effects on multiple cancer hallmarks. The 
compound is currently undergoing clinical evaluation for 
chemopreventive activity, including a phase II trial in lung 
cancer.
Recent findings have indicated that PEITC inhibits 
mRNA translation [2–4]. mRNA translation has a high 
energy requirement and is subject to tight regulation, 
especially at the level of initiation. In fact, recent analyses 
have suggested that regulation of mRNA translation 
may play a role as great as transcription in controlling 
protein expression [5]. Translation initiation is mediated 
by eukaryotic initiation factors (eIF) that recruit the two 
subunits of the ribosome to the correct mRNA start codon 
and ensure delivery of the initiator methionine-loaded 
tRNA [6]. mRNA translation is classically initiated in a 
5′-cap-dependent manner, where the 5′-cap of mRNA is 
recognized by the eIF4F complex comprising the 5′-cap-
binding protein, eIF4E, a helicase, eIF4A, and the scaffold 
protein, eIF4G. Additional eIFs are then recruited to 
modulate translation initiation rate and stringency of start 
codon selection. For example, eIF2B acts as a guanine 
nucleotide exchange factor for eIF2 (a trimer comprising 
α, β and γ subunits) and catalyzes the exchange of GDP 
to GTP that is required to form an active ternary complex 
after each round of translation initiation.
Modulation of eIF4E and eIF2 are pivotal for 
controlling mRNA translation [7]. eIF4E activity is 
regulated by the mTORC1 kinase complex via effects 
on eIF4E-binding proteins (4E-BPs) that sequester and 
inactivate eIF4E [8] and through direct phosphorylation 
of eIF4E by MAP kinase-integrating kinases (MNKs). 
[9] mTORC1-mediated 4E-BP phosphorylation triggers 
eIF4E release allowing binding to the mRNA 5′-cap 
and interaction with eIF4G. mTORC1 also regulates 
translation via p70S6K phosphorylation, thereby 
modulating ribosomal protein S6 activity [10, 11]. 
Initiation is also regulated by Ser51 phosphorylation of 
eIF2α. When phosphorylated at this site, eIF2α acts as a 
competitive inhibitor of eIF2B, thereby preventing ternary 
complex recycling and inhibiting translation [12]. eIF2α 
phosphorylation is typically induced as part of a stress 
response. For example, endoplasmic reticulum (ER) stress 
activates the eIF2α Ser51-specific kinase PERK leading to 
suppression of mRNA translation [12].
Dysregulation of mRNA translation plays a major 
role in cancer, acting to drive cell accumulation via effects 
on both global protein and specific proto-oncogenes 
which often have high requirements for translation [13]. 
Translationally regulated oncoproteins include MYC, 
a central regulator of cell growth, and HIF1A, which 
mediates pro-angiogenic responses in hypoxic conditions. 
Dysregulated mRNA translation in cancer cells is 
often associated with high levels of eIF4E, and eIF4E 
overexpression is sufficient to drive lymphomagenesis 
[14]. mTORC1 activation, associated with loss of negative 
regulatory tumor suppressor proteins (such as NF1 or 
PTEN), or inappropriate growth factor signaling, is also 
common in cancers. Overexpression of oncoproteins such 
as MYC can also lead to inappropriate mRNA translation 
[15] and eIF4E accelerates development of MYC-driven 
lymphoma [16]. Thus, MYC is intimately linked to mRNA 
translation since it is both a target for, and a major regulator 
of, mRNA translation. Inhibition of mRNA translation is, 
therefore, an exciting new approach to cancer therapy [17]. 
In fact, a recent study demonstrated the effectiveness of 
chemical inhibition of mRNA translation as a strategy 
to counter MYC-driven tumorigenesis in vivo, whereas 
inhibition of signaling upstream of MYC was circumvented 
by complex cross-talk mechanisms [18].
Despite the importance of dysregulated protein 
synthesis for cancer, few studies have investigated effects 
of PEITC on these pathways. Hu et al. demonstrated that 
PEITC increased eIF4E expression and decreased 4E-BP1 
phosphorylation in PC-3 prostate cancer cells, and 
inhibited 5′-cap-dependent mRNA translation measured 
using artificial reporter assays [2]. More recently, we 
demonstrated that PEITC decreased HIF1α protein 
expression via inhibition of HIF1A mRNA translation 
in MCF7 breast cancer cells [3, 4]. This inhibitory effect 
appeared to be driven via inhibition of mTORC1 [4] which 
is required for optimal HIF1A mRNA translation.[19, 20]
Studies of translational regulation have almost 
exclusively used established cell lines. Although clearly 
of great value, it is possible that regulatory pathways are 
altered in these settings since long-term culture will select 
for more metabolically active cell variants. Therefore, 
analysis of mRNA translation in primary cancer cells 
is an important goal. Chronic lymphocytic leukemia 
(CLL) provides a powerful model system for the detailed 
molecular analysis of primary cancer cells. It is the most 
common B-cell malignancy [21] and provides access to 
large numbers of monoclonal malignant B cells from the 
blood of patients.
Antigenic stimulation of the cell surface 
B-cell receptor (BCR) is a major driver of malignant 
cell accumulation in vivo in CLL. BCR signaling 
responsiveness varies between individual samples and 
retained signaling capacity is associated with a poor 
outcome. Moreover, inhibitors of BCR-associated 
signaling kinases (such as the BTK inhibitor ibrutinib) 
are revolutionising therapy for B-cell malignancies [22]. 
Antigenic stimulation can be mimicked using agonistic 
anti-IgM antibodies and we showed previously that 
anti-IgM increased MYC expression in CLL cells in vitro 
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and that MYC was expressed in lymph nodes from CLL 
patients, the site of antigen engagement in vivo [23]. More 
recently we demonstrated that anti-IgM increased both 
global mRNA translation and translation of MYC mRNA 
in primary CLL cells in vitro [24]. These responses were 
partially inhibited by ibrutinib. Therefore, CLL is a well 
validated model to study translational control in primary 
malignant cells.
In this work, we investigated effects of PEITC on 
mRNA translation. We show that, in addition to inhibition 
of mTORC1, PEITC triggers rapid phosphorylation of 
eIF2α and that eIF2α phosphorylation is required for 
optimal PEITC-mediated translational inhibition in mouse 
embryo fibroblasts (MEFs). PEITC also inhibited both 
basal and anti-IgM-induced mRNA translation in primary 
CLL cells (including translation of the MYC mRNA) and 
this was associated with both mTORC1 inhibition and 
increased eIF2α phosphorylation.
RESULTS
PEITC inhibits mRNA translation in MCF7 cells 
in a dose and time dependent manner
We first investigated effects of PEITC on global 
mRNA translation in human breast cancer-derived MCF7 
cells using metabolic labeling and polysome profiling. 
PEITC was used at concentrations up to 20 μM, based 
on previous published studies [4, 25]. PEITC profoundly 
inhibited metabolic labeling (Figure 1A). Inhibitory 
effects were dose-dependent with half-maximal response 
at between 2.5 μM and 5 μM. When evaluated using 
polysome profiling, PEITC (20 μM) completely blocked 
formation of polysomes (actively translated mRNA 
associated with multiple ribosomes) with concurrent 
accumulation of mRNA in the 80S monosome peak 
(Figure 1B and Supplementary Figure S1A). Inhibition 
of polysome formation was essentially complete at 
10 minutes post-treatment. Therefore, PEITC triggers a 
profound and rapid inhibition of global mRNA translation 
in MCF7 cells.
We previously showed that PEITC inhibited 
mTORC1 activity [4]. Although this would be expected to 
reduce mRNA translation, mTORC1 inhibition generally 
has modest inhibitory effects on global mRNA translation 
since it predominantly affects a subset of mRNAs whose 
5'-untranslated region (5'-UTR) contains highly structured 
5′-terminal oligopyrimidine motifs, including HIF1A [26]. 
To determine directly whether mTORC1 inhibition could 
account for the profound inhibition of mRNA translation 
induced by PEITC, we investigated effects of the mTORC1 
inhibitor, rapamycin. Analysis of phosphorylation of the 
mTORC1 substrate p70S6K confirmed effectiveness of 
the inhibitor at concentrations down to 1 nM (Figure 1C). 
However, even when tested at 25 nM, rapamycin 
only modestly reduced mRNA translation in MCF7 
cells measured using metabolic labeling (Figure 1D) 
or polysome profiling (Supplementary Figure S1B). 
Therefore, PEITC-mediated translational inhibition must 
involve other targets in addition to mTORC1.
PEITC induces eIF2α phosphorylation and 
induces stress granule formation
We next investigated effects of PEITC on 
phosphorylation of eIF2α, a second major regulatory arm 
for mRNA translation. Immunoblot analysis demonstrated 
that PEITC induced strong eIF2α phosphorylation in 
MCF7 cells (Figure 2A, 2B). Similar to inhibition of 
mRNA translation, induction of eIF2α phosphorylation 
was concentration dependent (Figure 2A, 2B) and rapid 
(Supplementary Figure S2). Therefore, in addition to 
mTORC1 inhibition, PEITC also promotes rapid eIF2α 
phosphorylation.
To begin to probe the functional significance of 
PEITC-induced eIF2α phosphorylation, we investigated 
the potential formation of stress granules, which is 
tightly linked to increased eIF2α phosphorylation [27]. 
Stress granules are cytoplasmic aggregates of stalled pre-
initiation complexes, containing translationally silenced 
mRNA, the 40S ribosomal unit and some eIFs. Following 
treatment with PEITC (20 μM), immunofluorescent 
imaging demonstrated co-localisation of the two specific 
stress granule markers, eIF3b and TIA-1, [28] within 
cytoplasmic complexes (Figure 2C, 2D and Supplementary 
Figure S3). Stress granules were infrequent in control cells 
(less than 1 in 10 cells) but abundant following PEITC 
treatment (~10 granules per cell; Figure 2E). The number 
of stress granules induced by 10 μM PEITC was similar to 
that induced by thapsigargin (40 μM), a known inducer of 
eIF2α phosphorylation and stress granule formation (data 
not shown).
PEITC-induced eIF2α phosphorylation is 
required for optimal inhibition of global  
mRNA translation 
To investigate directly the relevance of eIF2α 
phosphorylation for PEITC-induced translational inhibition, 
we analyzed responses in MEFs expressing either wild-
type eIF2α (S/S) or mutant eIF2α (with alanine substitution 
of Ser51) which cannot undergo Ser51 phosphorylation 
(A/A) [29]. Similar to MCF7 cells, PEITC induced eIF2α 
phosphorylation in S/S cells, but (as expected) not in A/A 
cells (Figure 3A). By contrast, PEITC-induced inhibition 
of mTORC1, measured by p70S6K phosphorylation, was 
similar in S/S cells and A/A cells.
We used metabolic labeling to quantify mRNA 
translation in eIF2α S/S and A/A cells. PEITC inhibited 
metabolic labeling in both cell types, but A/A cells were 
clearly less sensitive compared to S/S cells (Figure 3B). 
Similar results were obtained using polysome profiling 
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Figure 1: PEITC inhibits global mRNA translation in MCF7 cells. (A) MCF7 cells were incubated with the indicated concentrations 
of PEITC, DMSO (solvent control), or were left untreated as a control. After one hour, mRNA translation was quantified using metabolic 
labeling. Graph shows means (± SEM) derived from three independent experiments, each performed in duplicate, with values for untreated 
cells set to 1.0. Statistical significance of differences between PEITC and DMSO treated cells is shown (Student’s t-test). (B) MCF7 cells 
were incubated with PEITC (20 μM) or DMSO as a control. After the indicated times, polysome profiling was performed. The position of 
80S and polysomes are indicated. Data are representative of three separate experiments. (C) MCF7 cells were treated with the indicated 
concentrations of rapamycin, DMSO, or were left untreated as a control. After three hours, expression of total and phosphorylated p70S6K 
and β-actin (loading control) was analyzed using immunoblotting. Experiment shown is representative of three independent experiments. 
(D) MCF7 cells were incubated with rapamycin (25 nM) or left untreated as a control. After one hour, mRNA translation was quantified using 
metabolic labeling. Graph shows means (± SEM) derived from duplicate determinations, with values for untreated cells set to 1.0. 
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Figure 2: PEITC induces eIF2α Ser51 phosphorylation and stress granule formation. (A, B) MCF7 cells were treated with 
the indicated concentrations of PEITC, DMSO, or were left untreated as a control. After three hours, total and phosphorylated eIF2α and 
β-actin were analyzed by immunoblotting. (A) Representative experiment and (B) quantitation, derived from three independent experiments 
each performed in duplicate. Graph shows means (± SEM) with values for untreated cells set to 1.0. Statistical significance of differences 
between PEITC and DMSO treated cells is shown (Student’s t-test). (C–E) MCF7 cells were treated with PEITC (20 μM) or DMSO for 
30 minutes. (C) Immunofluorescence images for DAPI (nuclear stain), eIF3 and TIA-1 staining. Images are representative of three 
independent experiments. (D) Confocal microscopy. The fluorescent images show merged results for eIF3 and TIA-1 with overlapping 
signals shown in yellow (Figure S3). Left hand panels show cross-sectional intensities for eIF3 and TIA-1 staining for one stress granule 
(indicated). (E) Quantitation of eIF3/TIA-1 positive stress granules. Results obtained from analysis of four fields each from three independent 
experiments. A color version of C and D is presented as Figure S3.
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where PEITC ablated polysome formation in S/S cells, 
but had partial effects in A/A cells (Figure 3C). Therefore, 
eIF2α phosphorylation is required for optimal PEITC-
induced inhibition of mRNA translation.
We also used metabolic labeling to directly 
investigate the role of mTORC1 in PEITC-mediated 
inhibition of global mRNA translation. We compared 
inhibitory effects of PEITC in wild-type MEFs, and MEFS 
lacking TSC2, an upstream negative regulator of mTORC1 
[30, 31]. Both wild type and TSC2-deficient MEFS were 
also deficient for p53 since TSC2 deficiency results in cell 
senescence that is rescued by p53 deletion [32]. Similar to 
wild-type eIF2α S/S MEFs, PEITC also inhibited global 
mRNA translation in these MEFs (Figure 3D). However, 
there was no evidence that inhibition of metabolic 
labeling by PEITC differed between wild-type and TSC2-
deficient cells. Thus, consistent with results obtained using 
rapamycin in MCF7 cells (Figure 1D), PEITC-mediated 
inhibition of mTORC1 activity does not appear to make a 
major contribution to effects of PEITC on global mRNA 
translation. However, it is important to recognise that, 
despite the clear importance of eIF2α phosphorylation 
for inhibition of mRNA translation in MEFs revealed 
by analysis of eIF2α (A/A) mutant cells, higher 
concentrations of PEITC did inhibit mRNA translation in 
the absence of eIF2α phosphorylation (Figure 3B). These 
effects may be mediated via secondary inhibitory effects 
on mTORC1 and/or additional pathways.
We attempted to identify the kinase(s) responsible 
for PEITC-induced eIF2α phosphorylation focusing on the 
ER-resident eIF2α Ser51-specific kinase PERK. PEITC 
increased PERK phosphorylation at Thr980 (a marker of 
activation) in both eIF2α S/S and A/A MEFs (data not 
shown). However, siRNA mediated knock-down of PERK 
in MCF7 cells (~75% reduction of PERK expression) only 
partly decreased PEITC-induced eIF2α phosphorylation 
by ~50% (data not shown). Thus, the kinase(s) required 
for PEITC-induced eIF2α phosphorylation remains to 
be identified. Despite optimization of transfections, it 
is not clear whether there was sufficient residual PERK 
to mediate effective eIF2α phosphorylation, or whether 
response involves multiple, perhaps compensating, kinases.
PEITC inhibits mRNA translation and BCR 
signaling in CLL cells 
We next probed effects of PEITC in primary CLL 
cells. We investigated effects of PEITC on both basal (ie, 
in unstimulated cells treated with a control antibody) and 
anti-IgM-induced mRNA translation. mRNA translation 
was quantified at 24 hours, consistent with our previous 
study [24]. Anti-IgM signaling responses vary between 
samples and we selected a cohort of samples all of 
which were considered as signaling responsive based on 
our previous criteria [33]. The features of the selected 
samples (some of which were analysed in our previous 
study), including sIgM expression and signal capacity, and 
prognostic markers (IGHV mutation status, ZAP70/CD38 
expression) are shown in Supplementary Table S1.
We first investigated effects of PEITC using 
metabolic labeling. CLL cells undergo spontaneous 
apoptosis in vitro, and this can be accelerated by PEITC 
[34]. We selected a maximum concentration of 10 μM for 
our studies, and restricted exposure to PEITC to the final 
5 hours of the 24 hour anti-IgM treatment to minimise 
potentially confounding effects of apoptosis. Cells were 
also treated with the caspase inhibitor Q-VD-OPh to 
suppress apoptosis; cell viability analysis confirmed 
that there was no evidence for significant PEITC-
induced cell killing under our experimental conditions 
(Figure 4A). Consistent with our recent findings, [24] 
anti-IgM increased metabolic labeling in CLL cells. 
PEITC significantly inhibited basal and anti-IgM-induced 
metabolic labeling (both by~50%) (Figure 4B).
Although the samples selected for study typically 
contained a high proportion of CLL B-cells, we also 
used OPP-labeling [35] to specifically quantify mRNA 
translation within the malignant clone. OPP-labeling was 
combined with staining with anti-CD19 and anti-CD5 
antibodies to identify CLL cells, and scatter analysis was 
used to gate on viable cells [24]. OPP-labeling confirmed 
that PEITC inhibited both basal and anti-IgM-induced 
mRNA translation within the malignant clone (Figure 4C). 
In this assay, PEITC completely blocked basal translation. 
Effects on anti-IgM-induced mRNA translation were 
partial (~30% reduction) and did not achieve statistical 
significance.
We investigated effects of PEITC on phosphorylation 
of eIF2α and p70S6K at 60 minutes post-stimulation. 
PEITC was tested at both 10 and 20 μM in these shorter 
term experiments. As shown previously, [24, 36] anti-
IgM alone increased p70S6K phosphorylation in CLL 
cells (by ~3-fold), but had only modest effects on eIF2α 
phosphorylation (~50% increase; Figure 4D, 4E). PEITC 
had no effect on p70S6K phosphorylation in control cells, 
but significantly inhibited the response to anti-IgM (~40% 
reduction). By contrast, PEITC significantly increased 
eIF2α phosphorylation in the presence or absence of 
anti-IgM (Figure 4D, 4E). Therefore, PEITC counters 
anti-IgM-induced mTORC1 activation, and activates eIF2α 
phosphorylation in the presence or absence of anti-IgM in 
CLL cells. Due to very small amount of cytoplasm in CLL 
cells, we were unable to investigate the formation of stress 
granules in these cells.
As a control, we also investigated effects of 
PEITC on phosphorylation of ERK1/2 which is activated 
downstream of the BCR independent of mTORC1 and 
eIF2α. PEITC had no effect on ERK1/2 phosphorylation in 
control cells, and did not inhibit anti-IgM-induced ERK1/2 
phosphorylation (Figure 4D, 4E). In fact, PEITC modestly 
increased anti-IgM-induced ERK1/2 phosphorylation, 
consistent with effects of PEITC in other cell types [37].
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Figure 3: eIF2α phosphorylation is required for optimal PEITC-induced inhibition of mRNA translation. (A–C) eIF2α 
S/S and eIF2α A/A MEFs were treated with indicated concentrations of PEITC, DMSO, or were left untreated as a control. (A) After three 
hours, total and phosphorylated p70S6K and eIF2α, and β-actin were analyzed by immunoblotting. (B) After one hour, mRNA translation 
was quantified using metabolic labeling incubation for a further two hours giving a total PEITC treatment time of three hours. Graph shows 
means (± SEM) derived from three independent experiments, each performed in duplicate, with values for DMSO treated cells set to 1.0. 
Statistical significance of differences between PEITC and DMSO treated cells for each line is shown (Student’s t-test). (C) After one hour, 
mRNA translation was analyzed using by polysome profiling. Experiments shown are representative of three independent experiments. (D) 
As for (B), but using TSC2+/+p53−/− and TSC2−/−p53−/− MEFs.
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Figure 4: Effect of PEITC on basal and anti-IgM-induced mRNA translation in primary human leukemia cells. (A–C) 
CLL samples (n = 7) were treated with Q-VD-OPh (5 μM) and then stimulated with anti-IgM or control antibody. After 17 hours, cells 
were treated with PEITC (10 μM) or DMSO as a solvent control for an additional five hours. (A) Cell viability was determined by Annexin 
V staining. The graph shows the mean (± SEM) percentage of viable (annexin V−) cells relative to control antibody/DMSO-treated cells 
derived from three independent experiments, each performed in duplicate. (B) mRNA translation was quantified using metabolic labeling, 
or (C) OPP-labelling. (D, E) CLL samples were treated with PEITC (10 or 20 μM) or DMSO as a control and stimulated with anti-IgM, 
or control antibody for 60 minutes, expression of phosphorylated and total p70S6K, ERK1/2 and eIF2α was analyzed by immunoblotting. 
(D) Representative immunoblot. (E) Quantitation of multiple samples following 60 minutes of treatment (n = 5–8 for p70S6K; n = 3–6 for 
ERK1/2; n = 4 for eIF2α). Graphs show means (± SEM) with values for control cells set to 1.0. Statistical comparisons between groups are 
shown (Student’s t-test).
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PEITC inhibits anti-IgM-induced transcription 
and translation of the oncogene MYC
To further investigate effects of PEITC on mRNA 
translation in primary CLL cells, we examined effects of 
PEITC on MYC. We used Q-PCR to quantify MYC mRNA 
in fractions derived from polysome profiles. Anti-IgM 
enhanced both MYC RNA transcription and translation 
since anti-IgM increased the total amount of MYC mRNA 
recovered from the fractions, as well as the amount of 
MYC mRNA specifically present in polysome associated 
fractions (Figure 5A–5C) [24]. Translation responses 
were observed regardless of whether we determined the 
absolute amount of MYC mRNA in polysome fractions 
(Figure 5B) or the proportion of polysome-associated MYC 
mRNA (Figure 5C) which measures translation changes, 
independent of changes in the overall levels of MYC 
mRNA. PEITC significantly reduced anti-IgM-induced 
MYC mRNA transcription and translation (Figure 5A–5C). 
PEITC also effectively decreased anti-IgM-induced MYC 
expression (Figure 5D, 5E).
PEITC enhances inhibitory effects of ibrutinib 
on mRNA translation and viability in CLL cells
We previously demonstrated that the BTK inhibitor, 
ibrutinib, partially inhibited anti-IgM-induced mRNA 
translation [38]. To investigate whether PEITC could 
enhance responses to ibrutinib in CLL, we analysed effects 
of combinational treatment on anti-IgM-induced OPP-
labeling. The combination of PEITC and ibrutinib caused 
significant greater inhibition of anti-IgM-induced mRNA 
translation compared to either agent alone (Figure 6A). 
Moreover,  the combination of PEITC and ibrutinib also 
induced higher levels of CLL cell death compared to 
single agent treatments (Figure 6B).
DISCUSSION
Dysregulation of protein synthesis plays a critical 
role in carcinogenesis and there is considerable interest 
in chemical compounds that inhibit mRNA translation as 
potential anti-cancer agents [17]. We previously showed 
that the phytochemical PEITC inhibited mTORC1 
activity and downstream HIF1A mRNA translation [4]. 
In this work, we investigated effects of PEITC on mRNA 
translation using both established cell lines and primary 
leukemic cells.
We demonstrated that PEITC rapidly inhibited 
global mRNA translation and used genetically-manipulated 
MEFs to define the role of mTORC1 inhibition and eIF2α 
phosphorylation in this response. Although mTORC1 
inhibition seems to mediate PEITC-induced inhibition 
of HIF1A mRNA translation (which is highly dependent 
on mTORC1 signalling), [19, 20] mTORC1 inhibition 
appeared to make little contribution to effects of PEITC 
on global mRNA translation. Thus, mutation of eIF2α to 
prevent its activation via phosphorylation significantly 
reduced cell sensitivity to PEITC-mediated translational 
inhibition whereas deletion of TSC2 (which prevents 
PEITC-mediated mTORC1 inhibition) [4] did not alter 
responses. However, it is important to note that PEITC 
retained some inhibitory activity in eIF2α mutant MEFs. 
It is possible that mTORC1 inhibition contributes to 
PEITC-mediated translational inhibition alongside eIF2α 
phosphorylation, but does not play a substantial role alone. 
However, we do not exclude the possibility that PEITC 
may exert effects on additional regulatory pathways not 
investigated in these experiments.
The mechanisms by which PEITC induces eIF2α 
phosphorylation remain to be determined. Similar to 
a recent study in ovarian cancer cell lines, [39] we 
demonstrated that PEITC activated the ER-resident 
eIF2α kinase PERK in MCF7 cells. PEITC leads to 
the accumulation of reactive oxygen species (ROS) via 
depletion of glutathione, including in MCF7 [40] and 
CLL cells [34]. The ER is normally a relatively oxidizing 
environment and may therefore be particularly susceptible 
to PEITC-induced increases in ROS. However, results 
using PERK-specific RNAi were inconclusive, possibly 
due to residual PERK expression despite optimization of 
knock-down conditions.
Long-term culture of established cell lines is likely 
to be associated with selection of variants with high 
mRNA translation and a major goal of our study was to 
extend analysis to leukemic primary cells, using CLL 
as a model. PEITC inhibited both basal and anti-IgM-
induced global mRNA translation in CLL cells. Overall, 
PEITC appeared more effective in inhibiting basal, 
compared to anti-IgM-induced global mRNA translation. 
Pathway analysis revealed that PEITC increased eIF2α 
phosphorylation in the presence or absence of sIgM 
stimulation, and partially decreased anti-IgM-induced 
p70S6K phosphorylation. Thus, in the absence of sIgM 
stimulation, where mRNA translation is low and mTORC1 
is not activated, inhibitory effects of PEITC appear 
to be mediated via eIF2α phosphorylation. Following 
stimulation, mRNA translation inhibition may be mediated 
by combined effects of PEITC on eIF2α and mTORC1. 
The partial inhibition of anti-IgM-induced p70S6K 
phosphorylation by PEITC may explain why PEITC only 
partially inhibited induced global mRNA translation. 
Alternately, it is possible that sIgM stimulation activates 
additional pathways not studied here to promote mRNA 
translation and that these operate independently of PEITC. 
Potential candidates include the MNK1/2 kinases activated 
downstream of ERK/p38 MAPK which can also enhance 
mRNA translation in other cell systems [7]. Interestingly, 
in contrast to partial effects on global protein synthesis, 
PEITC completely suppressed anti-IgM-induced MYC 
RNA translation. MYC RNA has a highly structured 
5′-UTR and its translation therefore may be particularly 
affected by modest reductions in mTORC1-signalling.
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Figure 6: Effect of PEITC in combination with ibrutinib on cell viability and mRNA translation. (A) CLL cells were 
stimulated with anti-IgM for a total of 24 hours in the presence or absence of ibrutinib (10 μM) and/or PEITC (10 μM). For ibrutinib 
treatment, cells were pretreated with drug for 1 hour before addition of anti-IgM. For PEITC, cells were treated with drug for the final 
5 hours of BCR stimulation. DMSO was used as a solvent control. mRNA translation was then quantified by OPP-labeling. Graph show 
means (± SEM) with values for anti-IgM treated cells set to 100%. Statistical significance of differences between indicated groups are 
shown (Student’s t-test), n = 4. (B) CLL cells were treated with 10 μM ibrutinib for 24 hours alone, 10 μM PEITC alone for 5 hours, a 
combination of 10 μM ibruintib for 24 hours and 10 μM PEITC for the final 5 hours. DMSO was used a solvent control. Cell viability was 
determined by AnnexinV PI staining. Bars (± SEM) represent the percentage of viable cells (annexinV and PI double negative cells), n = 5. 
P values are indicated from paired Wilcoxon non-parametric t-test.
Figure 5: Effect of PEITC on MYC regulation. CLL cells (n = 7) were stimulated with anti-IgM or control antibody. After 17 hours, 
cells were treated with PEITC (10 μM) or DMSO as a solvent control for an additional 5 hours. (A–C) Analysis of monosome/polysome 
associated MYC mRNA using Q-PCR. Graphs show quantitation of (A) total MYC mRNA (monosomal plus polysomal); (B) polysome-
associated MYC mRNA; and (C) polysome/monosome ratio for MYC mRNA. Graphs show means (± SEM) with values with control 
antibody treated cells set to 1.0. Statistical significance of differences between indicated groups are shown (Student’s t-test). (D) Analysis 
of MYC protein expression by immunoblotting and (E) quantification.
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Despite substantial improvements in patient 
outcomes following the introduction of new targeted 
agents such as ibrutinib, CLL remains an incurable disease 
with a pressing need for novel therapeutic approaches. In 
our previous study, [38] we demonstrated that ibrutinib 
only partially inhibited anti-IgM-induced mRNA 
translation. Importantly, here we demonstrate that the 
combination of PEITC and ibrutinib resulted in almost 
complete blockage of anti-IgM-induced mRNA translation 
and that combined drug treatment was also associated 
with enhanced cytotoxic activity. Pronounced inhibitory 
effects on mRNA translation may stem from combined 
effects on both the mTORC1 and eIF2α-mediated arms of 
translational control. PEITC has been shown previously 
to promote apoptosis of CLL cells [34] and our study 
provides a potential rationale for combinatorial testing 
using PEITC to enhance responses to ibrutinib.
In conclusion, PEITC exerts inhibitory effects on 
both global and oncogene-specific mRNA translation, 
including MYC, via multiple pathways. These effects may 
contribute to both the chemo-preventive and anti-cancer 
effects of PEITC, and could be used to boost the efficacy 
of other agents, such as ibrutinib.
MATERIALS AND METHODS
Cell culture
The MCF7 cell line was obtained from American 
Type Culture Collection and cultured in complete 
Dulbecco’s Modified Eagle Medium (DMEM), ie 
supplemented with 10% (v/v) bovine fetal serum, 2 mM 
L-glutamine and 1% (v/v) penicillin/streptomycin mix (all 
PAA Somerset, UK). MEFs containing wild type eIF2α 
(MEF eIF2α S/S) and MEFs containing the homozygous 
eIF2α Ser51Ala mutation (MEF eIF2α A/A) were 
kindly provided by Professor R. Kaufman, University 
of Michigan Medical Center, USA [29]. TSC2-deficient 
(p53−/−TSC2−/−) and matched control MEFs (p53−/−
TSC2+/+) were kindly provided by Drs. A Tee (Cardiff 
University, UK) and D. Kwiatkowski (Brigham and 
Women’s Hospital, Boston, MA, USA) [32]. MEFs were 
cultured in complete DMEM.
Primary malignant B cells were obtained from the 
blood of CLL patients, as described [24]. Patients provided 
written informed consent in accordance with Ethics 
Committee approvals and the Declaration of Helsinki. 
Briefly, heparinized peripheral blood mononuclear cells 
were isolated using Lymphoprep (Axis-Shield, Oslo, 
Norway) and cryopreserved. Following recovery, cells 
were rested for one hour at 37°C prior to use. Cell viability 
determined by trypan blue exclusion was ≥ 90% and the 
median proportion of CD5+CD19+ CLL cells was 95% 
(range 82–99%). Molecular markers and sIgM signaling 
capacity were analyzed as previously described [33].
PEITC and the caspase inhibitor Q-VD-OPh were 
from Sigma Chemicals (Poole, UK). Cycloheximide 
(Sigma Chemicals) was used as a positive control for 
inhibition of RNA translation and was used at 10 µg/ml 
in the final five minutes of incubation. For B-cell receptor 
(BCR) stimulation, CLL samples were incubated with 
bead-bound goat F(ab’)2 anti-human IgM or control 
antibodies, as described [41]. Ibrutinib was from 
SelleckChem (Suffolk, UK).
mRNA translation assays
Polysome profiling, 35S-Met/Cys metabolic labeling 
and OPP assays [35] were performed as previously 
described [24]. For MCF7 cells and MEFs, metabolic 
labeling was performed for 2 hours and polysome profiling 
used 3 × 106 cells. For CLL cells, metabolic labeling was 
performed during the final 5 hours of cell incubations and 
polysome profiling used 10 × 107 cells. 
Immunoblot analysis
Immunoblot analysis was performed using the 
following antibodies; anti–T202/Y204-phosphorylated 
ERK1/2, anti-ERK1/2, anti-T389-phosphorylated p70S6K, 
anti-p70S6K, anti-S51-phosphorylated eIF2α, anti-
eIF2α (all Cell Signaling, Herts, UK), anti-MYC (9E10; 
Calbiochem, Nottingham, UK) anti-β-actin (Sigma 
Chemicals). Analysis used equal protein loading following 
quantitation of protein content using the BioRad Protein 
Assay (BioRad, Hemel Hempstead, UK). Secondary 
antibodies were HRP-conjugated rabbit, mouse or goat 
antibodies (Dako, Cambridgeshire, UK) and images 
were captured using the ChemiDoc-It Imaging System 
with a BioChemi HR camera (UVP, Cambridge, UK). 
Immunoblot signals were quantified using ImageJ (http://
imagej.nih.gov/ij/). For quantitation of phosphorylation, 
expression values were normalized to the loading 
control (β-actin) and then the relevant total protein. For 
quantitation of MYC, expression values were normalized 
to β-actin.
Immunofluorescence and confocal microscopy
Immunofluorescence and confocal microscopy was 
carried out on cell lines grown on coverslips and fixed 
using 4% (w/v) paraformaldehyde (BDH Laboratory 
Supplies, Poole, UK) and permeabilised using 0.1% 
(v/v) Triton X-100 (Sigma Chemicals).  Staining was 
carried out using anti-eIF3b (Santa Cruz, Heidelberg, 
Germany), anti-TIA-1 (Abcam, Cambridge, UK) and 
DAPI (Sigma Chemicals) was used as a nuclear stain. 
Coverslips were mounted onto microscopy slides using 
mounting media (Dako). Cells were imaged on the 
Olympus immunofluorescence microscope and captures 
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using the Olympus 1 × 81 Camera (Olympus, Essex, UK). 
For confocal microscopy images were captures on a 
Leica microscope using the LAS AF software (Leica 
Microsystems, Milton Keynes, UK).
Cell viability assays
Cell viability was analyzed using annexin V/
propidium iodide staining as described [28].
Statistics
Statistical comparisons were performed using 
Student’s t-tests (Prism 6 software, GraphPad Software, 
La Jolla, CA, USA).
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